Literature DB >> 2583049

Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist.

I Gozes1, E Meltzer, S Rubinrout, D E Brenneman, M Fridkin.   

Abstract

Vasoactive intestinal peptide (VIP) has been suggested as a neurotransmitter mediating penile erection. We now show that VIP can stimulate sexual behavior in rats with reduced masculine potential due to pituitary grafting or castration. This effect was attenuated in the presence of a novel VIP antagonist, devised by a hybrid peptide strategy. Thus, we have synthesized a molecule combining a portion of VIP with a portion of neurotensin, peptides of opposite pharmacological action on cAMP formation and smooth muscle relaxation. The hybrid peptide markedly inhibited VIP's effect on sexual behavior. This inhibition was manifested by a significant increase in the mean interval between copulatory events (greater than 3-fold change) coupled with a blockade of VIP-stimulated ejaculation. Other putative VIP antagonists were not as effective in blocking these activities. Thus, our results imply that VIP is not only associated with penile erection, but is involved in sexual behavior as well. Furthermore, the hybrid antagonist was shown to inhibit VIP binding in glial cell cultures. The availability of highly potent VIP antagonists may offer a route to study the possible multiple VIP receptors as well as help delineate other biological activities attributable to VIP.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2583049     DOI: 10.1210/endo-125-6-2945

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  29 in total

1.  VIP-PACAP 2010: my own perspective on modulation of cognitive and emotional behavior.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2010-11       Impact factor: 3.444

2.  Intestinotrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in mice.

Authors:  Bernardo Yusta; Dianne Holland; James A Waschek; Daniel J Drucker
Journal:  Endocrinology       Date:  2012-04-24       Impact factor: 4.736

3.  VIP, from gene to behavior and back: summarizing my 25 years of research.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2008-07-08       Impact factor: 3.444

4.  VIP blockade leads to microcephaly in mice via disruption of Mcph1-Chk1 signaling.

Authors:  Sandrine Passemard; Vincent El Ghouzzi; Hala Nasser; Catherine Verney; Guilan Vodjdani; Adrien Lacaud; Sophie Lebon; Marc Laburthe; Patrick Robberecht; Jeannette Nardelli; Shyamala Mani; Alain Verloes; Pierre Gressens; Vincent Lelièvre
Journal:  J Clin Invest       Date:  2011-08       Impact factor: 14.808

Review 5.  A VIP hybrid antagonist: from developmental neurobiology to clinical applications.

Authors:  I Gozes; M Fridkin; D E Brenneman
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

6.  Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene.

Authors:  I Gozes; J Glowa; D E Brenneman; S K McCune; E Lee; H Westphal
Journal:  J Mol Neurosci       Date:  1993       Impact factor: 3.444

7.  Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse.

Authors:  P Gressens; J M Hill; B Paindaveine; I Gozes; M Fridkin; D E Brenneman
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

8.  Inhibition of rat colon contractility by prostacyclin (IP-) receptor agonists: involvement of NANC neurotransmission.

Authors:  Y M Qian; R L Jones
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

9.  Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo.

Authors:  Eliezer Giladi; Joanna M Hill; Efrat Dresner; Conor M Stack; Illana Gozes
Journal:  J Mol Neurosci       Date:  2007-10-02       Impact factor: 3.444

10.  A fatty neuropeptide. Potential drug for noninvasive impotence treatment in a rat model.

Authors:  I Gozes; M Fridkin
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.